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The Y-box protein-1 (YB-1) belongs to the family of cold
shock proteins that have pleiotropic functions such as gene
transcription, RNA splicing, and mRNA translation. YB-1 has a
critical role in atherogenesis due to its regulatory effects on
chemokine CCL5 (RANTES) gene transcription in vascular
smooth muscle cells. Since CCL5 is a key mediator of kidney
transplant rejection, we determined whether YB-1 is involved
in allograft rejection by manipulating its expression. In
human kidney biopsies, YB-1 transcripts were amplified 17-
fold in acute and 21-fold in chronic allograft rejection with a
close correlation between CCL5 and YB-1 mRNA expression
in both conditions. Among three possible YB-1 binding sites
in the CCL5 promoter, a critical element was mapped at
28/10 bps. This site allowed up-regulation of CCL5
transcription in monocytic THP-1 and HUT78 T-cells and in
human primary monocytes; however, it repressed
transcription in differentiated macrophages. Conversely, YB-1
knockdown led to decreased CCL5 transcription and
secretion in monocytic cells. We show that YB-1 is a cell-type
specific regulator of CCL5 expression in infiltrating T-cells and
monocytes/macrophages and acts as an adaptive controller
of inflammation during kidney allograft rejection.
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Immunosuppressive regimens for renal transplant patients
have improved over the last decades. Nevertheless, the
occurrences of one or more episodes of acute allograft
rejection are highly predictive of a shortened transplant
survival.1,2 A key event for acute as well as chronic transplant
rejection is in both cases the recruitment of inflammatory
cells from the circulation into the renal allograft. Such
alterations may be classified according to the Collaborative
Clinical Trials in Transplantation (CCTT) criteria for
diagnosis of renal allograft pathology.3 These encompass,
among others, alloantigen activated T and monocytic cells.4,5
Experimental data revealed that the leukocyte recruitment
into transplants is mediated by chemokines and chemokine
receptors.6,7 Blockade of chemokine receptors or neutraliza-
tion of single chemokines reduces the degree and in some
instances even prevents the occurrence of (acute) transplant
rejection in experimental models.8–11 Although there is
substantial knowledge on underlying immunologic mechan-
isms that trigger and orchestrate organ loss in acute as well as
chronic rejection, it is still far from complete. A pivotal role
in mediating recruitment of immune cells has been attributed
to the C-C chemokine ‘regulated upon activation, normal T
cell expressed and secreted’ (RANTES/CCL5) that is shown
to be upregulated in acute transplant rejection.12 In a rat
kidney transplant model, the application of Met-RANTES, a
specific CCL5 antagonist,13 ameliorated acute and chronic
allograft rejection.14 In rat tissue and human biopsies with
transplant rejection CCL5 mRNA expression was localized to
tubular epithelial, endothelial cells, and infiltrating mono-
nuclear cells by in situ hybridization and real-time PCR.15
Bone marrow-borne monocytes travel through peripheral
blood vessels along gradients of chemoattractants. Once they
reach a target tissue, a local gradient of chemokines permit
them to infiltrate and propagate a process denoted ‘differ-
entiation’ into macrophages.16,17 Cell recruitment as well as
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the monocytic cell differentiation process are triggered and
orchestrated by several factors, such as interferon-g, CCL5,
cell-surface receptor CCR2, and transcription factor
Foxp1.16,18
The cold shock proteins are highly conserved in evolution
and are involved in a wide variety of cellular functions, such
as regulation of DNA transcription,19,20 RNA splicing,21 and
translational control of protein synthesis.22 The prototypic
member, denoted Y-box (YB) protein-1, has been shown to
associate with DNA elements encompassing inverted CAATT-
box sequences (Y boxes). YB-1 may act as a cell-type-specific
regulator of gene transcription,23 with preferential binding to
single-stranded DNA.20 Recent evidence from our laboratory
hints at a pivotal regulatory role for YB-1 in CCL5 gene
transcription and atherogenesis.24 These results prompted us
to hypothesize that YB-1 is also involved in kidney transplant
rejection by triggering CCL5 expression.
RESULTS
Under circumstances of renal allograft rejection YB-1
transcript numbers are upregulated in human kidneys
Given our hypothesis that YB-1 is relevant for CCL5
expression in kidney transplant rejection, we first quantified
YB-1 transcript numbers in biopsy samples obtained from
patients classified into five distinct groups by immuno-
histochemistry. In kidney tissue obtained from human living
donors without abnormalities (n¼ 8), cadaveric donors
(n¼ 8) and patients with minimal change glomerulonephri-
tis (n¼ 8), average transcript numbers were equal and set as 1
(Figure 1a). Compared to these groups transcript numbers
were markedly upregulated in kidney tissue with CCTT I
(n¼ 7; 17.4±20.8) and CCTT II transplant rejection (n¼ 8;
20.7±23.8), as depicted in Figure 1a. The intrarenal
expression levels of CCL5 in biopsy samples are shown in
Figure 1b.
YB-1 and CCL5 transcript numbers correlate in acute and
chronic transplant rejection
In the same human kidney biopsies quantification of CCL5
transcript numbers was performed and the correlation
coefficients were calculated. A highly significant correlation
between the expression of both transcripts was present in
acute (R2¼ 0.875) and chronic rejection (R2¼ 0.847; Figure
1c). When outliers were removed from statistical analyses, the
correlation coefficient in acute transplant rejection even
slightly increased (R2¼ 0.895), whereas the coefficient in
chronic rejection was lower (R2¼ 0.626) however still
statistically significant.
Cell-type-specific effects of YB-1 on the CCL5 promoter
activity
As YB-1 and CCL5 transcript numbers correlate under
conditions of renal allograft rejection and previous studies
demonstrated a cell-type-specific regulation of target genes
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Figure 1 | YB-1 and CCL5 expression correlate in renal allograft rejection. Quantification of YB-1 (a) and CCL5 (b) transcript numbers
was performed in biopsy samples from human kidney transplants (NTX living donor, cadaver, CCTTs I and II) and patients with
minimal changes glomerulonephritis (MC-GN) collected in the renal cDNA bank in Munich. Biopsies were scored according to the CCTT
criteria. YB-1 and CCL5 mRNA abundance was normalized to 18S rRNA content. Data are expressed as mean values±s.d. (c) Correlation of
YB-1 and CCL5 expression in human kidney biopsies with acute and chronic transplant rejection.
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by YB-1,23,25 we characterized the trans-regulatory effect that
YB-1 has on the CCL5 promoter in the context of different
cell lines. The YB-1 content of rat mesangial cells (MCs) was
manipulated by ectopic overexpression and knockdown using
a Tet-off system and small-interfering RNA.20 The corre-
sponding transcript numbers of YB-1 and CCL5 revealed a
direct, linear correlation over a broad range of transcript
numbers (Figure 2a). This result indicated a direct influence
of YB-1 protein levels on CCL5 gene transcription in MCs.
In the human HUT78 T-cell line, ectopic expression of
YB-1 elicited an up to fourfold increase of promoter
activity (Figure 2b, left panel) that was paralleled by
upregulation of CCL5 transcript numbers (middle panel)
and a fivefold increase in secreted protein (right panel).
Given that the CCL5 mRNA levels were only 40% higher
the data furthermore suggest that posttranslational effects
on CCL5 synthesis take place. Notably, depletion of
endogenous YB-1 content by introducing short-hairpin
RNA led to lower CCL5 transcript numbers (middle panel,
white columns).
A similar response on CCL5 gene transcription and
protein synthesis was observed in monocytic THP-1 cells
(Figure 3a). Knockdown of endogenous YB-1 resulted in a
significantly lowered CCL5 secretion rate (Figure 3a, right
panel, white column).
Contrary to these findings, overexpression of YB-1 in a
mouse macrophage cell line, RAW264.7, resulted in suppres-
sion of CCL5 promoter activity (Figure 3b, left panel). This
negative effect of YB-1 on CCL5 expression was also seen at
the protein level with a reduction of secreted CCL5 protein
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Figure 2 | Trans-regulation of the CCL5 promoter by YB-1 in rat mesangial cells and and T cells. (a) The effects of modified YB-1
content on CCL5 expression were determined at transcript level (RT-qPCR) by gradual depletion (shRNA) or overexpression (Tet-off system)
of YB-1 in rat mesangial cells. All experiments were done at least in triplicate and repeated three times. Data are expressed as mean
values±s.d. (b) CCL5 promoter activity (left panel), mRNA (middle panel) and protein synthesis (right panel) were determined in human
T lymphocytes (HUT78). A plasmid harboring the proximal 1014 bp of the 50 regulatory sequence in context of a luciferase reporter gene
was introduced to assess for YB-1 trans-regulation. Normalized luciferase activities were determined in three independent experiments,
each performed in triplicate. Data are expressed as mean values±s.d. Secreted CCL5 protein in the cell supernatant was quantified using
ELISA technology and normalized to control transfection. The cellular YB-1 content was manipulated by introducing pSG5-YB-1 expression
plasmid or achieving a knockdown with shYB-1.
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by 50%. A YB-1 knockdown resulted in marginally elevated
CCL5 protein levels in the supernatant (right panel, white
columns).
Our analyses for potential YB-1-binding sites within the
proximal human CCL5 promoter revealed three sequence
elements that exhibit significant similarities with conserved
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Figure 3 | Trans-regulation of the CCL5 promoter by YB-1 in monocytes/macrophages. CCL5 promoter activity (left panel) and protein
synthesis (right panel) were determined in (a) monocytes (THP-1) and (b) macrophages (RAW 264.7). Normalized luciferase activities were
determined in three independent experiments, each performed in triplicate. Data are expressed as mean values±s.d. (c) Inspection of the
proximal human CCL5 promoter and comparison with known YB-1-binding motifs of the matrix metalloproteinase-2 (MMP-2) and DNA
polymerase-a (DPA) genes revealed three putative YB-1-binding sites harboring homologies and an inverted repeat motif (indicated by
arrows). Reporter construct analysis was performed using two plasmids harboring the proximal 1014 or 168 bp of the 50 regulatory
sequence of the CCL5 promoter. The solid lines on the left represent the DNA content for each of the CCL5 reporter constructs as indicated
by number. The putative YB-1-binding sites present in each construct are represented by small boxes. Relative promoter activity for each
vector in THP-1 and RAW264.7 cells is indicated graphically as an average on the right side of the diagram. All experiments were done in
triplicate. Data are expressed as mean values±s.d. (d). Sequence homology between the human and murine CCL5 promoter are shown for
the proximal YB-1-binding site III (28/10 bp).
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YB-1-binding motifs of the metalloproteinase-2 and DNA
polymerase-a genes. These are known to be directly trans-
regulated by YB-1 binding (Figure 3c). A truncated CCL5
promoter construct (168/þ 1 bp), carrying solely the
proximal YB-1-binding site III, was sufficient for YB-1
trans-regulation and a cell-type-specific effect of YB-1 in
monocytes and macrophages was apparent (Figure 3c). The
proximal putative YB-1-binding site is highly homologous
between the human and rat CCL5 genes, as depicted in
Figure 3d.
Taken together, these results indicate a context-dependent
effect of YB-1 on the CCL5 promoter in T cells and
monocytic cells versus differentiated macrophages. Next we
wanted to assess whether the opposing effects were due to the
differentiation process from monocytes to macrophages. To
mimick the situation of infiltrating monocytes with ensuing
differentiation to macrophages, we added phorbol 13-
myristate 12-acetate (PMA) and followed over time the cell
differentiation process.26
Influence of YB-1 on CCL5 expression during PMA-induced
monocytic cell differentiation
Phorbol 13-myristate 12-acetate-dependent effects on mono-
cytes include changes in cell shape (Figure 4a), endocytosis
rates, and shedding of membrane proteins, all of which
resemble a more macrophage-like state.
Incubation with PMA led to a more than threefold
increase of CCL5 promoter activity within 6 h, which
tapered off in the subsequent observation period until 48 h
(Figure 4b). There was a markedly increased CCL5 synthesis
rate in PMA-treated cells, with CCL5 protein content in the
conditioned cell culture medium reaching more than 10-fold
elevated levels after 48 h compared to control cells
(Figure 4c).
Overexpression of YB-1 in nonstimulated THP-1 cells led
to significantly increased CCL5 promoter activity, as reported
above (compare Figure 3a). Subsequent to PMA addition,
within 6 h, the trans-stimulatory effect of ectopic YB-1
expression was no longer present for the ensuing time points
(Figure 4d), nor did the CCL5 secretion change significantly
under these conditions (Figure 4f). The little impact of YB-1
on CCL5 expression during PMA stimulation might be
explained by the degradation of the protein (as can be seen in
Figure 5). Depletion of endogenous YB-1 levels by introdu-
cing short-hairpin RNA had the expected inhibitory effect on
the CCL5 promoter in cells that were not treated with PMA
(Figure 4e). However, after PMA addition, the cells showed a
significant induction of promoter activity by YB-1 knock-
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Figure 4 | Phorbol ester-dependent THP-1 cell differentiation and changes of CCL5 promoter activity. (a) The cell morphology of
THP-1 cells, untreated or exposed to 100 nM PMA for 48 h, changes from nonadherent globular morphology to adherent cells with
cytoplasmic extensions. (b) The activity of the CCL5 promoter (proximal 1014 bp) was determined following PMA stimulation in THP-1
monocytes. (c) Cell culture supernatants of THP-1 cells were collected after 72 h of incubation with PMA addition for the indicated time
periods (black bars). CCL5 protein synthesis and secretion was assessed by ELISA. In the absence of PMA only minor amounts of CCL5
are accumulated during the time course (gray bars). (d, e) The CCL5 promoter activity was determined in THP-1 cells with increased YB-1
content (d) or depletion of YB-1 (e) over time following incubation with phorbol ester (PMA). (f) Influence of YB-1 overexpression
(black bars) or knockdown (gray bars) on PMA-stimulated CCL5 secretion in THP-1 cells. Representative results of three independent
experiments performed as triplicates are shown. Data are expressed as mean values±s.d.
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down that was observed after 6, 24 and 48 h (Figure 4e), with
a threefold induction of the CCL5 promoter activity and
subsequent protein secretion (Figure 4f) after 48 h. Thus, in
accord with the results obtained with the macrophage cell
line RAW264.7, YB-1 has a suppressive effect on the CCL5
promoter in ‘differentiated’ THP-1 cells. The suppressive
effect of YB-1 in differentiated cells seems to be maximal, as
further overexpression of YB-1 was not able to suppress
CCL5 gene transcription markedly. On the other hand, YB-1
knockdown was very effective in increasing CCL5 transcrip-
tion rates.
Endogenous cellular YB-1 protein levels are downregulated
during PMA-induced monocyte cell differentiation
As YB-1 overexpression influenced the CCL5 promoter in
monocytes and macrophages in opposing directions, we were
interested to determine whether endogenous YB-1 protein
levels change in the differentiation process. By immunoblot-
ting using a YB-1-specific antibody a transient increase of
nuclear YB-1 was detected following PMA incubation for 6 h.
Subsequently, YB-1 protein content in the cytoplasm as well
as in the nucleus was lower, starting around 24 h (Figure 5a).
After 48 h YB-1 protein was only detectable in both
compartments following extended exposure of the immuno-
blots. When the same blot was probed with an antibody
specific for DNA-binding protein-A, another member of the
cold shock protein family, it became apparent that the
cellular YB-1 protein content was specifically downregulated
in the course of monocytic cell differentiation (Figure 5b, bar
diagram).
Following PMA incubation for 6 h, YB-1 transcript
numbers were upregulated (Figure 5c, left). Thereafter, a
biphasic response was apparent with downregulation within
24 h and minor upregulation after 48 h. At the same time
points, CCL5 transcript numbers gradually rose over the time
period of 48 h (Figure 5c, right). These results suggest that
not only protein degradation, for example, through
N-terminal protein cleavage indicated by ** in Figure 5a,
may be of relevance for the downregulated cellular YB-1
content in ‘differentiated’ THP-1 cells but may also be that
YB-1 gene transcription rates and/or the mRNA half-life is
markedly decreased.
To confirm these findings in primary cells, human
monocytes were harvested from human volunteers and
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Figure 5 | Transient nuclear shuttling and subsequent degradation/downregulation of YB-1 expression in differentiating THP-1
cells. (a) Cytoplasmic (CE) and nuclear proteins (NE) of THP-1 cells were analyzed for YB-1 content in the course of PMA-dependent
monocyte differentiation using a YB-1-specific polyclonal antibody. Separation of cell compartments and equal protein loading were
ensured by determining GAPDH and CREB levels. (b) Protein content of cold shock proteins YB-1 and DbpA during PMA-induced monocyte
differentiation. Band intensities were quantified and are shown as bar graph. (c) YB-1 and CCL5 transcript numbers were quantified by
quantitative TaqMan analyses at different time points following PMA incubation of THP-1 cells and (d) during serum-induced differentiation
of primary human monocytes on days 2 and 6. The data represent three independent experiments performed as triplicates. Primary cultures
from four different blood donors produced similar results. (e) A comparison of YB-1 protein content in monocytic THP-1 cells and RAW264.7
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analyzed. YB-1 and CCL5 mRNA levels were determined in
these nondifferentiated cells and compared to cells incubated
for 2 or 6 days with human serum to induce differentiation to
macrophage-like cells. In accordance to the results in THP-1
cells, a transient increase and subsequent downregulation of
YB-1 was demonstrated during differentiation of primary
cells (Figure 5d, left). The CCL5 transcript numbers were
transiently upregulated threefold at day 2 of serum-induced
differentiation, whereas after 6 days of serum incubation
CCL5 expression was lowered to values of undifferentiated
cells.
To directly compare the endogenous YB-1 protein levels in
monocytic THP-1 cells and the macrophage cell line
RAW264.7, cytoplasmic and nuclear protein extracts were
compared by immunoblotting. The results indicate an
approximately fivefold lower YB-1 content in the macro-
phage cell line compared to monocytic cells (Figure 5e).
Mapping of YB-1-binding sites within the human CCL5
promoter
Previous studies performed with human smooth muscle cells
demonstrated the physical and functional interaction of YB-1
with the distal-binding site (denoted I in the schematic
overview Figure 4c) located at 205/174 bp of the human
CCL5 promoter.24 In the following, we evaluated the two
more proximal-binding sites for YB-1 binding.
Under the chosen conditions, YB-1 binding was not
present to site II (185/163), neither the sense nor the
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Figure 6 | YB-1 binds to a sequence motif within the proximal CCL5 promoter. (a) DNA-binding analyses of the 28/10 bp element
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for binding with recombinant YB-1 protein. HomC, homologous competitor DNA; HeterC, heterologous competitor. (b) Nuclear protein
extracts from monocytic THP-1 cells and RAW264.7 cells were prepared and complex formation with the anti-sense (SS2, 28/10 bp)
probe was assessed. A strong nucleoprotein complex appeared with THP-1 protein extract (filled arrowhead), whereas it was markedly
weaker with RAW264.7 cell extracts. Participation of YB-1 in the complex formation was confirmed by supershift analyses (SS*) using a
YB-1-specific, but not nonspecific rabbit IgG antibody. With RAW264.7 cell extracts an additional, low-mobility complex is detected (empty
arrowhead). This complex is absent in the presence of YB-1-specific antibody. NS, nonspecific complexes; LS, loading slot.
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anti-sense strands, using recombinant protein or nuclear
extracts from THP-1 cells (data not shown).
In contrast to the above results, two distinct complexes
were detected with the anti-sense oligonucleotide (SS2)
containing the proximal site (III, 28/10 bp) together with
recombinant YB-1 (Figure 6a, lanes 8 and 14). As described
for numerous other target genes,20,27 a very weak interaction
was seen with the double-stranded oligonucleotide (lane 11),
whereas no complexes appeared with the sense strand
(SS1; lane 5) or with a scrambled control oligonucleotide
(lane 2).
To further confirm specificity of the protein:DNA
interaction, a titration experiment with inclusion of homo-
logous and heterologous competitors DNA was performed.
As expected, a concentration-dependent competition was
observed with homologous competitor DNA, whereas even in
the presence of high concentrations of scrambled oligonu-
cleotide no change of complex formation was seen (Figure 6a,
lanes 15–18).
Differences of DNA:protein complexes at the site III of the
CCL5 promoter in monocytes and macrophages
As YB-1 exerts opposing effects on the CCL5 promoter in
monocytes and macrophages, we compared the binding to
the anti-sense strand encoding for site III with nuclear
protein extracts from THP-1 and RAW264.7 cells. A strong
complex was detected with THP-1 nuclear protein (Figure 6b,
lane 1, filled arrowhead) that corresponds in its mobility to
the one observed with recombinant YB-1 protein (Figure 6a,
lanes 8 and 14). Inclusion of YB-1-specific antibody resulted
in a supershift (lane 2, SS*), whereas an irrelevant antibody
(lane 3) had no effect. These results emphasize the binding
specificity of YB-1 with this promoter region.
In contrast to THP-1 cells, the DNA:protein complex was
only weak with nuclear proteins from RAW264.7 cells (Figure
6b, lane 4, filled arrowhead). A distinct low mobility band
was present (open arrowhead), that just entered the gel and
separated from the loading slot (LS). This complex also
includes YB-1 protein, as its formation was abrogated in the
presence of a YB-1 specific (lane 5), however not a
nonspecific antibody (lane 6).
DISCUSSION
Chemokines, especially CC-chemokines such as CCL5, MIP-
1a, MIP-1b, and MCP-1, as well as CXC-chemokines such as
IL-8 and IP-10 are known to contribute to renal transplant
rejection.28–30 The kinetics and molecular control mechan-
isms involved in CCL5 transcription/expression vary among
cell types31,32 and the blockade of chemokine receptors by
Met-CCL5 diminishes early infiltration and activation of
mononuclear cells into grafts.13 Thus, understanding me-
chanisms of CCL5 gene regulation may provide important
insights that can be utilized to prevent or ameliorate
transplant rejection.
There are a few reports on the regulative role of YB-1 in
inflammatory diseases, such as allergic asthma, mesangio-
proliferative glomerulonephritis, and thrombin-dependent
endothelial cell activation.33–35 Otherwise the focus of most
YB-1 studies has been on its role in cancerogenesis36,37 as well
as tumor progression.38,39 YB-1 has been originally cloned
with a regulatory element of the HLA-DR gene promoter40
and further investigations demonstrated a repressive effect of
YB-1 on interferon-g-dependent major histocompatibility
protein expression.41 Furthermore, YB-1 regulates the
expression of granulocyte-macrophage colony-stimulating
factor25 and markedly prolongs the half-life of IL-2 mRNA
in T cells and thereby its translation efficacy.22 Similar
posttranscriptional regulation events have also been de-
scribed for CCL5 mRNA, for example by RFLAT-1, regulating
CCL5 synthesis in T lymphocytes in response to stress
situations.42 These finding indicate that YB-1 may also be
relevant in the immunologic response of allotransplant
rejection. Analyses from our group recently demonstrated
that YB-1 serves as a transcriptional regulator of CCL5
expression in human arterial smooth muscle cells,
thereby contributing to neointimal and medial hyperplasia
in an experimental model for accelerated atherosclerosis in
apoE/ mice.24 As CCL5 is prominently expressed during
cell-mediated renal allograft rejection,28 we extended our study
to human kidney transplants and investigated the impact of
YB-1 on CCL5 expression in MCs and immune cells typically
present in cellular infiltrates during transplant rejection.
Intrinsic kidney cells, such as MCs, are known to fulfill
numerous functions otherwise observed with immune cells,
for example, phagocytosis and MHC classes I and II
expression.43,44 Furthermore, they quickly upregulate CCL5
transcript numbers in response to TNFa stimulation, a
prototypic proinflammatory cytokine.31 We found a close
linear relationship between YB-1 and CCL5 expression in
MCs, as well as in T lymphocytes. A 21-fold induction of YB-
1 transcript numbers was apparent with allograft rejection. In
comparison, in control patients without increased CCL5
expression, for example, living donor allografts without
rejection and in kidneys with diagnosis of minimal change
disease, YB-1 transcript numbers were largely unchanged.
Therefore, YB-1 appears to be an important player in
modulating gene expression in this inflammatory event. A
highly significant correlation between the expression of YB-1
and CCL5 in acute and chronic rejection was determined,
rendering a direct influence of YB-1 on CCL5 expression
during renal transplant rejection very likely. By in vitro
analyses a proximal-binding motif within the CCL5 gene was
mapped as binding site for endogenous and recombinant
YB-1. Mutations of YB-1-binding sites en bloc or with dual
or single nucleotide substitutions have been performed
previously by our group for the collagen type I gene,
providing ambiguous results.45 These findings were in accord
with the notion that this transcription factor has no core-
binding motif and the reported inverted CCAAT box
(denoted Y-box) is not an absolute requirement and
unsufficient for binding. YB-1 interacts with extended
regions of DNA, therefore mutation analyses will likely not
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solve the question whether this promoter region is required
for YB-1 regulation.
Notably, not all patients with transplant rejection
exhibited markedly elevated YB-1 and CCL5 transcript
numbers, indicating that other mechanisms for rejection
may also exist. Currently, we perform gene expression
profiling to determine whether these groups may be
distinguished. In accordance with these findings, the delivery
of chemokine receptor antagonist Met-RANTES did not
completely prevent transplant rejection in a renal transplant
model.13
Infiltration of renal allografts by leukocytes is a hallmark
of acute transplant rejection. Peripheral blood monocytes
and T lymphocytes recruited to sites of inflammation adhere
to endothelial cells and transmigrate through vessel walls.
Leukocyte infiltration is accompanied by alteration of the
cellular phenotype and physiologic activities. To monitor
the YB-1 and CCL5 expression levels in this process, we used
the THP-1 monocytic cell line that displays macrophage-like
differentiation in response to phorbol esters.26 The expres-
sion patterns of both proteins, CCL5 and YB-1, were
temporally and differentially regulated during the process.
PMA stimulation induced YB-1 expression and nuclear
localization early-on (6 h), thereafter the cellular protein
content decreased over time during cell maturation, along
with a declined CCL5 promoter activity.
In human renal allografts, CCL5 receptors on infiltrating
interstitial macrophages have been reported to be lost, most
likely due to downregulation after transmigration.46 Several
transcription factor are known to control macrophage
development and directly control the acquisition of a mature
monocyte phenotype, for example, by induction of macro-
phage-specific genes, as do PU.1 and AML1.47 Other
transcription factors are involved in the maintenance of a
stem cell population, such as GATA-248 and are repressed at
early stages of myelopoiesis. Factors thought to orchestrate
the intermediate state of myelopoiesis, such as Foxp118 or
c-Myc,49 are highly expressed during the first stages of
differentiation and repressed before the end of maturation.
Notably, c-Myc and YB-1 are known to promote cell
proliferation, for example, by stimulating cyclin A and B1
expression.50,51
From studies with the gelatinase A52 and granulocyte-
macrophage colony-stimulating factor25 genes, it is known that
YB-1 may act as transcriptional activator and repressor of the
same gene, depending on the cellular context. For the first
time, we could demonstrate that the CCL5 gene is regulated
in a cell-type-specific manner by YB-1 and that this effect
depends on the cellular differentiation status. Furthermore,
the appearance of high mobility complexes in DNA-binding
studies with the site III-binding motif of the CCL5 promoter
(28/10 bp) indicates that partnering with other transcrip-
tion factors/cofactors occurs. This likely mediates the
repressive effect on gene transcription and to identify the
components of this complex is the focus of ongoing research.
Thus, YB-1 has the potential to initiate and later on to abate
the inflammation process, as depicted in the model of
Figure 7. As early infiltration by monocytes is a poor
prognostic sign for allograft survival and given our
identification of YB-1 as a key regulator of CCL5 expression
in nondifferentiated monocytes and T cells, YB-1 may be
useful as early target of incipient transplant rejection.
MATERIALS AND METHODS
mRNA expression levels in human renal biopsies and
cultured cells
Human renal biopsies were collected in a multicenter study (the
European Renal cDNA Bank/ERCB) after informed consent was
obtained according to the guidelines of the respective local ethical
committees (for ERCB members, see Appendix). Five groups of
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Figure 7 | Schematic model of YB-1 governing CCL5 synthesis during renal allograft rejection. Alloantigen-activated monocytes
recruited to the allograft infiltrate and differentiate into macrophages. During the onset of acute inflammation, YB-1 shuttles into the
nucleus and stimulates CCL5 expression that amplifies the inflammatory trigger by auto- and paracrine activity. During propagative
inflammation and macrophage differentiation, YB-1 is downregulated and gains trans-repressive capacity on the CCL5 promoter. After a
time lag, the CCL5 expression is shut down.
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renal biopsies available in ERCB were analyzed for relative
expression levels of YB-1 (NM_004559) in kidney tissue obtained
from human living donors without abnormalities (n¼ 8), kidneys
from cadaveric donors (n¼ 8), patients with minimal change
glomerulonephritis (n¼ 8), acute (n¼ 7) and chronic renal
transplant rejection (n¼ 8) using the CCTT modification for
diagnosis of renal allograft pathology, CCTT I and CCTT II.3
Amounts of YB-1 mRNA were determined by quantitative TaqMan
analysis and normalized for the 18sRNA content, as described.53 In
samples obtained from patients with acute (n¼ 7) or chronic
transplant rejection (n¼ 8), the relative content of CCL5 mRNA
(AF043341) was quantified in the same specimen and correlation
analysis was performed using Spearman’s equation.
Student’s t-test was used for comparisons between experimental
groups. Significant differences were defined at Po0.05.
Plasmids, cell lines, and culture conditions
A full-length YB-1 expression plasmid (pSG5-YB-1) was kindly
donated by J. Ting (Lineberger Comprehensive Center, University of
North Carolina, North Carolina, USA),27 plasmids encoding for
CCL5 promoter fused to the luciferase gene extended up to
974 bp. CCL5 promoter deletion construct (168/þ 1) has been
described.31,54 Knockdown of endogenous YB-1 by small-interfering
RNA was performed with pSuper vector harboring the sequence 50-
GGTCATCGCAACGAAGGTTTT-30 (OligoEngine, Seattle, WA,
USA) as a tail-to-tail tandem repeat of base pair 285–305 of the
human YB-1-coding sequence as described before.33 Rat MCs were
established and characterized as previously described.23 MC, human
HUT78 T-cell line, THP-1 (human monocytic cell line), and
RAW264.7 (mouse macrophage cell line) were grown in RPMI-1640
medium supplemented with 10% fetal calf serum, 2 mM L-glutamin,
100mg/ml streptomycin and 100 U/ml penicillin at 37 1C in
humidified 5% CO2 in air. Cell culture materials were purchased
from Gibco BRL (Gaithersburg, MD, USA).
Transient transfections, monocyte differentiation,
and luciferase measurements
Rat MC and mouse RAW 264.7 cells were transiently transfected
with lipid-based transfection reagent Fugene (Roche, Mannheim,
Germany) according to the manufacturer’s instruction. Human
THP-1 and HUT78 T cells were transfected by means of
electroporation. Briefly, nonadherent cells were pelleted and
resuspendend in electroporation medium supplemented with 20%
fetal calf serum at 2 107 cells per ml. Cells (250 ml; 5 106 cells)
were added to electroporation cuvettes (0.4 cm gap, Bio-Rad,
Hercules, CA, USA) together with a total amount of 20 mg plasmid
DNA in various combinations as outlined (pSG5, pSG5-YB-1, pGL3,
CCL5-promoter-pGL3, YB-1-short-hairpin RNA; b-GAL). The
mixture was incubated for 5 min (THP-1) or 10 min (HUT78) on
ice and electroporated at 250 V/975 mF (THP-1) or 200 V/1200 mF
(HUT78) in a Gene Pulser II electroporation system (Bio-Rad).
Cells were incubated another 5 min on ice before they were
resuspended in 4 ml of RPMI-1640 media supplemented with 20%
fetal calf serum and transferred to six-well tissue culture plates, and
incubated at 37 1C and 5% CO2 for 24 h.
THP-1 cells were induced to differentiate into adherent
macrophage-like cells by treatment with PMA (100 nM; Sigma-
Aldrich, St. Louis, MO, USA). Nontransfected cells were seeded at
2.5 106 cells per plate, electroporated cells (4 106 cells per
cuvette) were divided post-transfection onto six-well plates and
incubated for the indicated time periods. After treatment with PMA
differentiation occurs and cells adhere, become flat, and amoeboid
in shape.
Human peripheral blood mononuclear cells from healthy blood
donors were isolated by density gradient centrifugation by means of
buffy coats obtained from the local blood bank. Monocytes were
isolated by magnetic cell sorting using anti-CD14 antibody. Separated
cells were divided into three groups and stored at 80 1C (day 0) or
resuspended in RPMI-1640 that contained 5% human serum to allow
cells to adhere and differentiate for 2 or 6 days at 37 1C.
Luciferase activity was quantified using the Promega luciferase
assay system (Mannheim, Germany) in a Sirius luminometer
(Berthold Detection Systems). Results were confirmed in at least
three independent experiments and calculated as fold changes relative
to luciferase activity measured with promoterless pGL3 plasmid.
Nuclear and cytoplasmic cell extracts and western blot
analyses
Nuclear and cytoplasmic cell extracts were prepared as described
previously.23 Protein concentrations were determined by the Bio-
Rad protein assay using bovine serum albumin as standard. Extracts
were stored at 80 1C until subjected to SDS-polyacrylamide gel
electrophoresis. Proteins were transferred to nitrocellulose and
detected by suitable primary peptide-derived antibodies specific for
YB-1 and DNA-binding protein-A (antibodies-online, Aachen,
Germany), furthermore glyceraldehyde-3-phosphate dehydrogenase
or cAMP response element-binding protein and secondary perox-
idase-linked anti-mouse or anti-rabbit antibodies (Amersham
Biosciences, Piscataway, NJ, USA) using ECL (Amersham Bio-
sciences) as chemiluminescent. Band intensities were quantified
by OptiQuant software, whereas the YB-1 content in cells without
PMA treatment was set as 1 and relative band intensities were
calculated.
Electrophoretic mobility shift analyses
Recombinant YB-1 was prepared with a pRSET vector (Invitrogen,
Carlsbad, CA, USA) containing an insert encoding for a hexahis-
tidine T7 epitope-YB-1 fusion protein as described.52 Synthetic
DNA probes corresponding to the sense as well as antisense strands
of the CCL5 promoter sequences 185/174 and 28/10 bp were
end-labeled by means of the biotin 30 end DNA-labeling kit (Pierce,
Rockford, IL, USA). Double-stranded DNA was annealed by mixing
together equal amounts of complementary oligos and incubating the
mixture for 1 h at room temperature.
The nucleotide sequences were:
(185/163 bp): 50-CCGGTACCGGAAACTGATGAGCTCACT
CACTCTAGATGAGAGATCTGC-30
(28/10 bp): 50-CCGGTACCCCCCTCAACTGGCCCTATAA
AGGGCCAGCCTGAGATCTGC-30
Biotin-labeled DNA was incubated with affinity-purified recom-
binant YB-1 protein or nuclear cell extract for 20 min on ice and was
subjected to electrophoresis on native 6% PA gels. Following transfer
to nylon membranes bands were visualized by streptavidin-horse-
radish peroxidase conjugate and chemiluminescent substrate (Light-
Shift chemiluminescent EMSA kit, Pierce).
For supershift analyses, peptide-derived affinity-purified rabbit
YB-1-specific antibody (antibodies-online, Aachen, Germany) was
incubated with nuclear proteins 12 h prior to addition of probes.
The binding reaction was performed as described above and samples
were subjected to electrophoresis on 6% polyacrylamide gels.
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Tetracycline-inducible YB-1 expression system in mesangial
cells
The Tet-off system was established as described.55 Briefly, stable
double transfection of rat MCs were constituted with regulatory,
response, and selection plasmids that are pTet-Off, pTRE-HA-YB-1,
and pTK-Hyg in the presence of selection media containing G418
(Calbiochem, San Diego, CA, USA) and hygromycin (Invitrogen).
Transfections were performed using effectene (Qiagen, Hilden,
Germany) according to the manufacturer’s recommendations. Single
cell colonies were grown in the presence of 1 mg/ml doxycyclin (ICN,
Aurora, OH, USA), and medium supplemented with fresh
doxycyclin was replaced every other day. Expression of HA-YB-1
at reduced doxycyclin concentrations (102, 104, and 106 mol/l)
was monitored by Western blotting using polyclonal anti-HA tag
antibody (Santa Cruz Biotechnology, CA, USA). All plasmids were
kindly donated by H Bujard (University Heidelberg, Germany)
except for pTRE-HA (BD Biosciences, San Jose, CA, USA).
Experiments have been performed as triplicates and were confirmed
in three independent experiments.
Enzyme-linked immunosorbent assay
Secreted CCL5 protein was assayed in cell culture medium of THP-
1, RAW264.7, and HUT78 T cells using the quantitative sandwich
enzyme immunoassay technique with reagents from R&D Systems
(DuoSet ELISA development kit DY278, Minneapolis, MN, USA).
The optical density was measured using a microplate reader set to
450 nm. All standards (diluted 1:2 and 1:10) and samples (super-
natants of THP-1 cells: 1:20, RAW264.7 cells: 1:5, HUT78 T cells:
1:30) were assayed as duplicates of at least two independent
experiments.
Statistical analysis
All values are expressed as means±s.d. Statistical significance was
evaluated using the Student’s t-test with significance accepted when
Po0.05.
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